AKINON
Akinon, a cloud-based headless commerce platform focused on major retailers and consumer brands, raised USD 20m in a Series B funding round co-led Actera Group and Revo Capital, with participation from SmartFin Capital and Endeavor Catalyst.
Akinon’s software, with its API first architecture, streamlines retail sales via online channels as well as physical stores, and provides end-to-end support in managing orders, user experience and customer data. As a cloud-based solution provider supporting digital transformation of leading global brands, Akinon has been a sought-after partner for numerous retailers across 17 countries, including Turkey, Russia, Ukraine, Poland, Hungary, Czech Republic, and Greece.
Akinon’s customer base ranges from small-to-medium size enterprises to larger clients with USD 1bn in revenue. At its home market Turkey, company serves around half of the top 100 retailers such as Lacoste, Marks & Spencer, Sephora, and Gap. The company charges a commission based on the gross merchandise value and managed USD 315m in GMV in 2020, growing at a rate of more than 150% year-over-year and plans to increase its annual GMV to more than USD 1bn in 2022.
Series B proceeds will be used to enhance global competitiveness of its services, boost its service quality, and step up its global growth by expanding into MENA, Eastern Europe and Asia.
Akinon co-founder and CEO Tolga Tatari commented on the funding: “We continue to work very hard with our strong team of 400 and plan to double that number in 2022. Our goal is to double our revenue next year by expanding in new regions where we plan to establish and work with local partners.”
The retail sector is on the inflection point in the history of retail where the distinction between online and brick-and-mortar retail has disappeared. More than ever businesses need effective and efficient ways to sell through multiple channels and plan to invest even more in the tools and experiences that will unite their digital and physical operations. Akinon helps its customers make the most of e-commerce enablement at a time when their traditional retail businesses have been disrupted, by dramatically expanding their revenue and market potential.
Tatari and his two co-founders, Ahmet Sari and Cagri Orcan are previously also founders of Markafoni, the leading e-commerce company of Turkey, which was acquired by Naspers in 2014.
Actera Group expressed their excitement: “We are excited to be backing a very experienced team in omnichannel commerce, and be a part of Akinon’s next phase of growth in Turkey and in international markets.”
Revo Capital’s Founding Partner & Managing Director Cenk Bayrakdar commented: “We are big believers in the strength of the management team to execute their vision to revolutionize commerce through its cloud-based omnichannel experience platform with an expanding set of tools and features.”
SmartFin Capital's Founding Partner Jurgen Ingels said: “We are just at the beginning of the cloud-based commerce platform revolution and we believe that Akinon has the technology and the experience to become one of the world leaders in that segment. This new capital round will allow us to increase our internationalization and service even more global companies.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005724/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 202631.12.2025 14:08:00 CET | Press release
Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended.Nurses worldwide can submit their nominations via www.asterguardians.com The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. T
Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release
Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release
The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
